ATP2C1

Across TCGA pan-cancer cohorts, ATP2C1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATP2C1 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATP2C1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATP2C1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where ATP2C1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.700	0.961	.003	33	view →
HNSC	DFS	Median	II,III,IV	0.875	0.689	.004	22	view →
LSCC	DFS	Quartile	All	0.574	0.872	.005	17	view →
PDAC	OS	Median	IV	0.381	0.951	.006	8	view →
UCEC	DFS	Tertile	III,IV	1.000	0.529	.049	4	view →
LUAD	DFS	Median	II,III,IV	0.179	0.731	.007	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP2C1–CCRCC (OS)

Open the CCRCC breakdown →